Omid Hamid
Impact in
- Oncology top 0.01%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Immunology top 0.1%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Oncology 323
- Cancer Immunotherapy and Biomarkers 203
- CAR-T cell therapy research 149
- Cutaneous Melanoma Detection and Management 39
- Colorectal Cancer Treatments and Studies 25
-
- Melanoma and MAPK Pathways 99
- Co-authors
- F. Stephen Hodi (62 shared papers)Jeffrey S. Weber (73 shared papers)Jedd D. Wolchok (41 shared papers)Steven O’Day (29 shared papers)Caroline Robert (57 shared papers)Célèste Lebbé (38 shared papers)David M. Berman (13 shared papers)Adil Daud (63 shared papers)
- Journals
- Journal of Clinical Oncology (188 papers)Annals of Oncology (49 papers)Clinical Cancer Research (18 papers)Cancer Research (17 papers)Journal for ImmunoTherapy of Cancer (14 papers)
- Partner nations
- United StatesFranceAustralia
In The Last Decade
Omid Hamid
400 papers receiving 26.2k citations
Omid Hamid's Hit Papers
Peers
Comparison fields: 5 of 131
- Oncology 18.4k
- Immunology 8.4k
- Biological Psychiatry 555
- Pulmonary and Respiratory Medicine 3.9k
- Cancer Research 1.5k
Countries citing papers authored by Omid Hamid
This map shows the geographic impact of Omid Hamid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Omid Hamid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Omid Hamid more than expected).
Fields of papers citing papers by Omid Hamid
This network shows the impact of papers produced by Omid Hamid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Omid Hamid. The network helps show where Omid Hamid may publish in the future.
Co-authors
The 25 scholars most cited alongside Omid Hamid, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 416 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria Hit paper breakdown → | 2009 | 2322 |
| 2 | Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma Hit paper breakdown → | 2015 | 1571 |
| 3 | Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial Hit paper breakdown → | 2016 | 940 |
| 4 | Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) Hit paper breakdown → | 2017 | 911 |
| 5 | Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial Hit paper breakdown → | 2012 | 830 |
| 6 | Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study Hit paper breakdown → | 2019 | 788 |
| 7 | Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study Hit paper breakdown → | 2019 | 726 |
| 8 | Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial Hit paper breakdown → | 2012 | 721 |
| 9 | Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer Hit paper breakdown → | 2016 | 663 |
| 10 | Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 Hit paper breakdown → | 2019 | 651 |
| 11 | An immune-active tumor microenvironment favors clinical response to ipilimumab Hit paper breakdown → | 2011 | 601 |
| 12 | Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma Hit paper breakdown → | 2017 | 482 |
| 13 | 2009 | 462 | |
| 14 | 2011 | 444 | |
| 15 | Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma Hit paper breakdown → | 2016 | 443 |
| 16 | Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study Hit paper breakdown → | 2013 | 439 |
| 17 | 2014 | 418 | |
| 18 | Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study Hit paper breakdown → | 2016 | 412 |
| 19 | Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer Hit paper breakdown → | 2015 | 383 |
| 20 | 2017 | 338 |
About Omid Hamid
Omid Hamid is a scholar working on Oncology, Molecular Biology, Immunology, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine, having authored 416 papers that have together received 26.7k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (203 papers), CAR-T cell therapy research (149 papers), Melanoma and MAPK Pathways (99 papers), Immunotherapy and Immune Responses (91 papers), Cutaneous Melanoma Detection and Management (39 papers), Monoclonal and Polyclonal Antibodies Research (34 papers), Cancer Research and Treatments (29 papers) and Colorectal Cancer Treatments and Studies (25 papers). The work is most often cited by research in Oncology (18.4k citations), Immunology (8.4k citations), Biological Psychiatry (555 citations), Pulmonary and Respiratory Medicine (3.9k citations) and Cancer Research (1.5k citations). Omid Hamid has collaborated with scholars based in United States, France and Australia. Frequent co-authors include F. Stephen Hodi, Jeffrey S. Weber, Jedd D. Wolchok, Steven O’Day, Caroline Robert, Célèste Lebbé, David M. Berman, Adil Daud, Michele Maio and Antoni Ribas. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Clinical Cancer Research, Cancer Research and Journal for ImmunoTherapy of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.